circadian clock comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
About 10–25% of gynecomastia cases are estimated to result from the use of medications or exogenous chemicals. Drugs can increase estrogen activity or increase the estrogen to androgen ratio through various mechanisms, such as binding to estrogen receptors, promoting estrogen synthesis, providing precursors that can be aromatized into estrogen, causing damage to the testes, inhibiting testosterone synthesis, inhibiting the action of androgens, or displacing estrogen from SHBG. Drugs with good evidence for association with gynecomastia include cimetidine, ketoconazole, gonadotropin-releasing hormone analogues, human growth hormone, human chorionic gonadotropin, 5α-reductase inhibitors such as finasteride and dutasteride, certain estrogens used for prostate cancer, and antiandrogens such as bicalutamide, flutamide, and spironolactone. Drugs with fair evidence for association with gynecomastia include calcium channel blockers such as verapamil, amlodipine, and nifedipine; risperidone, olanzapine, anabolic steroids, alcohol, opioids, efavirenz, alkylating agents, and omeprazole. Certain components of personal skin care products such as lavender or tea tree oil have been reported to cause prepubertal gynecomastia due to its estrogenic and anti-androgenic effects. Certain dietary supplements such as dong quai and Tribulus terrestris have also been associated with gynecomastia.
When the fetus is exposed to testosterone, the genital tubercle elongates (primordial phallus) and develops into the glans and shaft of the penis and the urogenital folds fuse to become the penile raphe. The urethra within the penis (except within the glans) is developed from the urogenital sinus.
15 September – The Sunday Times reports that Starmer may have broken parliamentary rules by failing to declare clothes bought for his wife, Victoria, by Labour donor Lord Waheed Alli. 16 September – Downing Street confirms that the Parliamentary Commissioner on Standards will not investigate whether Starmer broke parliamentary rules by not declaring a gift of clothes for his wife. The Welsh Government scraps plans to force parties in the Senedd to ensure 50% of their candidates are women. 18 September – Liberal Democrat leader Ed Davey unveils an expanded 33-member frontbench team following the party's gains at the general election. Former prime minister Sir John Major criticises the Sunak government's Rwanda asylum plan, describing it as "un-Conservative and un-British". Ofcom announces it will not investigate Ed Balls' interview with his wife, Home Secretary Yvette Cooper, on Good Morning Britain on 5 August despite receiving over 16,000 viewer complaints. ITV chief executive Dame Carolyn McCall defends the interview's impartiality, but says the broadcaster would not do it again. 20 September – Downing Street confirms that Keir Starmer, Angela Rayner and Rachel Reeves will no longer accept donations for clothing following controversy over gifts given to Starmer's wife. 22–25 September – The 2024 Labour Party Conference is scheduled to take place at the ACC Liverpool. 24 September – Starmer gives his keynote conference speech, setting out plans for "national renewal" but telling delegates there are no "easy answers".
Brilliant blue FCF (Blue 1) is a synthetic organic compound used primarily as a blue colorant for processed foods, medications, dietary supplements, and cosmetics. It is classified as a triarylmethane dye and is known under various names, such as FD&C Blue No. 1 or acid blue 9. It is denoted by E number E133 and has a color index of 42090. It has the appearance of a blue powder and is soluble in water and glycerol, with a maximum absorption at about 628 nanometers. It is one of the oldest FDA-approved color additives, having been permanently listed for use in food and ingested drugs in 1969. It is generally considered nontoxic and safe for consumption.
In 2025, CERN's ALICE experiment team announced that over the previous decade, they had used the Large Hadron Collider to replicate the 2002 SPS mechanisms at higher energies. A total of roughly 260 billion gold nuclei were created over three experimental runs, a minuscule amount of about 90 picograms. Startup Marathon Fusion proposes a theoretical way to make gold from mercury: use a nuclear fusion reactor to bombard mercury with high-energy neutrons, specifically 198Hg, an isotope with 10% abundance. This creates the unstable 197Hg, which then decays into stable gold (197Au) with a half-life of approximately 64 hours.
Sources: en.wikipedia.org
Antidepressant discontinuation syndrome, or antidepressant withdrawal, is a condition that can occur following switching, reducing, or discontinuing an antidepressant medication following its continuous use of at least a month. The symptoms may include dizziness, vertigo, postural orthostatic tachycardia syndrome (POTS), tinnitus, insomnia, nausea, poor balance, sensory changes, "brain zaps", emotional lability or extreme emotional changes, rage, suicidal ideation, akathisia, dysesthesia, intrusive thoughts, depersonalization and derealization, mania, anxiety, depression, stuttering, and flu-like symptoms. Psychosis may rarely occur. Depending on the specific antidepressant's half-life, withdrawal can begin within a few days or weeks, but late onset or delayed onset withdrawal can occur months after cessation. If stopped too quickly, a withdrawal injury can occur. This is referred to as protracted withdrawal and may last for several months or years. Discontinuation syndrome was coined by Eli Lilly as a way to distance antidepressants from other dependence-forming psychotropics with higher addiction risk profiles. However, the evidence supports that what has been mislabeled as discontinuation syndrome is a classical withdrawal syndrome similar to that of benzodiazepines. Antidepressants are not addictive and do not produce substance use disorders, but they do create physical dependence which occurs when the body makes neuroadaptations due to the presence of the drug.
The Southern Rhodesian economy grew considerably during the war despite the concurrent rise of war expenditure to pay for the expansion of the military and the air training scheme. Expenditure on the war grew from £1,793,367 in the financial year 1940–41 to £5,334,701 in 1943–44—total Southern Rhodesian expenditure on the air training scheme was £11,215,522. These sums, while tiny compared to those incurred by larger nations, were enormous when scaled against the white population of less than 70,000 that accounted for most of the colony's economic output. Annual costs for the air training scheme alone far exceeded the pre-war national budget. Southern Rhodesia was then the second largest gold producer in the world, after South Africa. The colony's gold output had expanded greatly during the 1930s, and it remained the territory's main source of income during the war, though many extracting operations were diverted towards strategic minerals, most prominently chrome and asbestos. Southern Rhodesia became one of the two main sources of chrome for the Allies (South Africa was the other) and the world's third largest producer of asbestos after Canada and the Soviet Union. By the end of the war the mines at Shabani and Mashaba were turning out 1.5 million tonnes of asbestos a year, in addition to 600,000 tonnes of chrome. Gold output reached peak levels in 1941–42 and thereafter subsided. Southern Rhodesia also exported tungsten, mica and tin, and provided coal for the copper mines of Northern Rhodesia and the Congo.
=== Subgroups or clusters within FM === There may be clusters of symptom characteristics within fibromyalgia. A 2024 systematic review found that fibromyalgia could be clustered according to symptom severity, adjustment to the condition, thermal pain sensitivity, personality, and response to treatment. However it stated there was a need for more objective measures, and for more validation and replication of clusters. Clustering has also been undertaken based on psychological and coping characteristics of FM people.
Zippe-type centrifuges use countercurrent multiplication between rising and falling convection currents to reduce the number of stages needed in a cascade. Some Centrifugal extractors use counter current exchange mechanisms for extracting high rates of the desired material. Some protein skimmers (devices used to clean saltwater pools and fish ponds of organic matter) use counter current technologies. Countercurrent processes have also been used to study the behavior of small animals and isolate individuals with altered behaviors due to genetic mutations.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.